Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer

Chalasani, Venu; Chin, Joseph L.; Izawa, Jonathan I.

doi:10.5489/cuaj.1195

Cited by 157 publications

(132 citation statements)

References 62 publications

(75 reference statements)

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…It has been hypothesized that the difference in prognosis may be due to resistance of tumors with glandular differentiation to chemotherapies directed at usual urothelial carcinoma-however, data supporting this hypothesis are lacking. In contrast, other studies 23,24 have suggested that glandular differentiation does not affect prognosis after adjusting for pathologic stage. Despite these controversies, it is recommended that divergent differentiation within a urothelial carcinoma should be documented in surgical pathology reports.…”

Section: Primary Glandular Maligancies Of the Bladdermentioning

confidence: 76%

Primary Adenocarcinoma of the Urinary Bladder: Differential Diagnosis and Clinical Relevance

Zhong

Gersbach

Rohan

et al. 2013

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.—Glandular lesions of the urinary bladder include a broad spectrum of entities ranging from completely benign glandular lesions to primary and secondary malignancies. Common benign bladder lesions that exhibit glandular differentiation include cystitis cystica, cystitis glandularis, von Brunn nests, nephrogenic adenoma, intestinal metaplasia, urachal remnant, endometriosis, and prostatic-type polyp. The World Health Organization defines primary adenocarcinoma of the bladder as an epithelial malignancy with pure glandular differentiation without evidence of typical urothelial carcinoma. Malignant lesions that should be included in the differential diagnosis of a primary adenocarcinoma of the bladder include noninvasive and invasive urothelial carcinoma with glandular differentiation and secondary malignancies involving the bladder by direct extension or metastasis. The recognition and distinction of these different entities may be a challenge for pathologists, but they are of great clinical importance. Objective.—To review features of primary bladder adenocarcinoma as well as those entities that need to be differentiated from primary bladder adenocarcinoma, with emphasis on clinical findings, pathologic characteristics, and immunoprofiles. Data Sources.—Selected original articles published in the PubMed service of the US National Library of Medicine. Conclusions.—The accurate diagnosis of adenocarcinoma of the urinary bladder is important and challenging. It has to prompt an extensive clinical workup to rule out other glandular lesions in the urinary bladder, especially the possibility of secondary involvement of the bladder by an adenocarcinoma from a different site.

show abstract

Section: Primary Glandular Maligancies Of the Bladdermentioning

confidence: 76%

Primary Adenocarcinoma of the Urinary Bladder: Differential Diagnosis and Clinical Relevance

Zhong

Gersbach

Rohan

et al. 2013

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…To our knowledge, no published articles have focused on treatment guidelines for sarcomatoid variant of urothelial carcinoma according to stage, although one group suggested that radical cystectomy rather than intravesical therapy should be the preferred option of treatment for patients with stage T1 disease. 9,10 Overall, prognosis of sarcomatoid carcinoma is poor, with a five-year survival of 20.3% after radical cystectomy.…”

Section: Discussionmentioning

confidence: 99%

Bladder preserving approach for liposarcomatoid variant of transitional urothelial carcinoma

Singh

Mittal

Mukhopadhyay

et al. 2015

CUAJ

View full text Add to dashboard Cite

Urothelial carcinoma of the bladder with variant histologies is usually underdiagnosed and understaged. It is found in <25% of cases during transurethral resection of bladder tumours. The majority of cases carry a worse prognosis, with higher rates of recurrence and progression, and should be managed aggressively. Here, we report a rare case of liposarcomatoid variant of urothelial carcinoma managed by partial cystectomy and standard pelvic lymph node dissection.

show abstract

“…UC is known to show variant histologic features otherwise known also as divergent differentiation, with estimates ranging from 7% to 81% in series reporting differentiation patterns ofUCs (6,7).…”

Section: Urothelial Carcinoma Variantsmentioning

confidence: 99%

A Contemporary Update and Pathology Reporting for Urinary Bladder Cancer

Mazzucchelli

Scarpelli

López-Beltrán

et al. 2012

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Providing the best management for patients with bladder cancer relies on close cooperation among uro-oncologists and pathologists. The pathologist is involved in the diagnosis and assessment of prognostic and therapeutic factors in bladder biopsies, transurethral resection (TUR) and cystectomy specimens. The pathologist must report accurately the key features using terms that are well understood by clinicians. Adequate clinical information is important to pathologists in deciding the best approach in handling and processing the surgical specimens.An open communication is essential for urooncologists and pathologists in the decision-making process for diagnosis and patient management (l). Adequate clinical information is important to pathologists in deciding the best approach in handling and processing the surgical specimens and directing the most essential information to be reported.The specimen requisition form must contain relevant information which the clinician can provide (2, 3). With differing implications for non-invasive papillary versus flat tumours and advent of enhanced cystoscopic visualization, the urologist's impression provides helpful information for the pathologist in difficult situations, such as when the entire lesion architecture is not obvious on the slides (e.g. fragmented or superficial sections).Information on the surgical procedure, such as for surveillance or post intravesical therapy biopsies, initial or second TUR (e.g. for deep muscle assessment or completion of resection), "early" or salvage cystectomy, among others, is important for pathologists in specimen handling and reporting. Presence of calculi, catheterization or infection may explain reactive changes. Other relevant information includes history of bladder cancer and prior intravesical or neoadjuvant chemotherapy. This review deals with a contemporary update on pathology reporting for urinary bladder cancer. HANDLING OF SPECIMENS BiopsyAll biopsy-sampled tissues should be submitted for processing. Effort should be made to identify the

show abstract

Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer

Cited by 157 publications

References 62 publications

Primary Adenocarcinoma of the Urinary Bladder: Differential Diagnosis and Clinical Relevance

Primary Adenocarcinoma of the Urinary Bladder: Differential Diagnosis and Clinical Relevance

Bladder preserving approach for liposarcomatoid variant of transitional urothelial carcinoma

A Contemporary Update and Pathology Reporting for Urinary Bladder Cancer

Contact Info

Product

Resources

About